Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024 Featured Updates to the NCCN Guidelines

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/ likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important up-dates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and manage-ment associated with TP53 P/LP variants and Li-Fraumeni syndrome.J Natl Compr Canc Netw 2023;21(10):1000-1010doi:10.6004/jnccn.2023.0051

Automated summary

The NCCN Guidelines focus on genetic/familial high-risk assessment for breast, ovarian, and pancreatic cancers. They provide recommendations for genetic counseling/testing and care strategies for individuals with pathogenic/likely pathogenic (P/LP) variants associated with increased risk. The updates include a new section for transgender, nonbinary, and gender diverse people, as well as testing criteria and management for TP53 P/LP variants and Li-Fraumeni syndrome.